Tabandeh Mohammad Reza, Taha Amal Sattar, Addai Ali Hanaa, Razijalali Mohammad, Mohammadtaghvaei Narges
Department of Basic Sciences, Division of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz 6135783151, Iran.
Department of Chemistry, Faculty of Science, University of Kufa, Najaf 54001, Iraq.
Biomedicines. 2023 Jan 25;11(2):346. doi: 10.3390/biomedicines11020346.
The alterations of circulating adipocytokines have been reported in thyroid diseases or type 2 diabetes mellitus (T2DM), but such data in T2DM coincident with clinical and subclinical thyroid-dysfunctions are limited, and remain to be investigated. We studied the changes in serum chemerin, resisitin and visfatin in T2DM patients with thyroid dysfunctions, and their association with inflammatory and insulin resistance-markers. A total of 272 female and male Iranian participants were selected and divided into six groups: the euthyroid group, T2DM, T2DM coincident with clinical and sub clinical hypothyroidism (SC-HO, and C-HO), and T2DM coincident with clinical and sub clinical hyperthyroidism (SC-HR, C-HR).Demographic characteristics, serum levels of adipocytokines, thyroid hormones, inflammatory factors (IL1-β, IL-6 and CRP) and insulin resistance-markers were determined in all participants. T2DM patients with clinical thyroid dysfunctions showed higher levels of circulating resistin, visfatin, chemerin and inflammatory factors, compared with the T2DM group and T2DM coexisted with subclinical thyroid diseases. No significant differences were observed in circulating adipocytokines and inflammatory markers between T2DM coexisting with subclinical thyroid diseases and those without thyroid dysfunctions. Our results revealed that clinical thyroid dysfunction in T2DM patients was associated with elevated levels of circulating resistin, chemerin, visfatin and inflammatory factors, while no such alteration was detected in T2DM coincident with subclinical thyroid dysfunction.
甲状腺疾病或2型糖尿病（T2DM）中循环脂肪细胞因子的改变已有报道，但T2DM合并临床和亚临床甲状腺功能障碍的此类数据有限，仍有待研究。我们研究了甲状腺功能障碍的T2DM患者血清chemerin、抵抗素和内脂素的变化，以及它们与炎症和胰岛素抵抗标志物的关系。总共选取了272名伊朗男女参与者，分为六组：甲状腺功能正常组、T2DM组、T2DM合并临床和亚临床甲状腺功能减退组（SC-HO和C-HO），以及T2DM合并临床和亚临床甲状腺功能亢进组（SC-HR、C-HR）。测定了所有参与者的人口统计学特征、脂肪细胞因子血清水平、甲状腺激素、炎症因子（IL1-β、IL-6和CRP）和胰岛素抵抗标志物。与T2DM组以及合并亚临床甲状腺疾病的T2DM患者相比，患有临床甲状腺功能障碍的T2DM患者循环抵抗素、内脂素、chemerin和炎症因子水平更高。合并亚临床甲状腺疾病的T2DM患者与无甲状腺功能障碍的患者在循环脂肪细胞因子和炎症标志物方面未观察到显著差异。我们的结果显示，T2DM患者的临床甲状腺功能障碍与循环抵抗素、chemerin、内脂素和炎症因子水平升高有关，而合并亚临床甲状腺功能障碍的T2DM患者未检测到此类改变。
